Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Pharmaceutical Biotechnology|October 7, 1998
Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucomaG S Ponticello, M F Sugrue, B Plazonnet, et al.Current Eye Research|June 1, 1990
A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animalsM F Sugrue, P Mallorga, H Schwam, et al.Journal of Medicinal Chemistry|May 1, 1981
Approaches to vasodilating/beta-adrenergic blocking agents: examples of the dihydrolutidine typeJ J Baldwin, R Hirschmann, E L Engelhardt, et al.Journal of Medicinal Chemistry|September 1, 1977
2-pyridylimidazoles as inhibitors of xanthine oxidaseJ J Baldwin, P K Lumma, F C Novello, et al.Journal of Medicinal Chemistry|August 1, 1977
An approach to peripheral vasodilator-beta-adrenergic blocking agentsJ J Baldwin, R Hirschmann, P K Lumma, et al.Journal of Medicinal Chemistry|July 1, 1983
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole classJ J Baldwin, G H Denny, R Hirschmann, et al.Investigative Ophthalmology & Visual Science|May 1, 1988
L-653,328: an ocular hypotensive agent with modest beta receptor blocking activityM F Sugrue, P Gautheron, J Grove, et al.Journal of Medicinal Chemistry|January 1, 1980
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridineJ J Baldwin, E L Engelhardt, R Hirschmann, et al.Journal of Ocular Pharmacology|January 1, 1990
MK-927: a topically active ocular hypotensive carbonic anhydrase inhibitorM F Sugrue, P Gautheron, J Grove, et al.Journal of Medicinal Chemistry|June 1, 1979
beta-Adrenergic blocking agents with acute antihypertensive activityJ J Baldwin, E L Engelhardt, R Hirschmann, et al.Pageof 2